OncoPharm

PVB's (cisplatin, vinblastine, bleomycin) impressive cure rate for testicular cancer is 1977 is discussed. Then the evolution of the BEP & EP regimen is summarized.

Abemaciclib's up-front approval provides an opportunity to review all 3 currently FDA-approved CDK 4/6 inhibitors. Dosing, drug interaction, and indication differences are discussed.

Durvalumab's FDA-approval for NSCLC and the supporting PACIFIC study are discussed, then the ASCO Immunotherapy Toxicity Management Guidelines (7:45) are reviewed. Also, a plug for patient support groups.

The discussion dives into the FDA approval of apalutamide for non-metastatic castrate-sensitive prostate cancer. It highlights its mechanism of action, dosing, and critical findings from the SPARTAN study. The potential drug interactions and side effects are also addressed, emphasizing the crucial role of pharmacists in monitoring patients. Additionally, updates from ASCO GU bring new insights into the use of DOACs in cancer treatment, adding further depth to the conversation.

The Landmarks series continues with Bonadonna's classic adjuvant CMF regimen in breast cancer in a pre-tamoxifen & pre-ER/PR testing era. Discussion points include number needed to treat (NNT) to prevent recurrence and how chlorambucil was considered for the 'C' in CMF.

Overview of doxorubicin from its Italian origins to its Red Devil alias. Uses and toxicities also discussed, of course.

New Drug Approval: Lutetium-177-dotatate is discussed as well as updates to indications for denosumab (m. myeloma), afatinib, & olaparib.

The Landmarks series continues with DeVita's original MOPP (Hodgkin's Disease) publication from 1970. Discussion points include WBC monitoring, why cyclophosphamide isn't included, and wigs.

The Foundations in Oncology Pharmacy series begins with the penicillin of oncology: cisplatin. Discussion of its history, current uses, & toxicities. Perfect for those new to oncology pharmacy.

Review of recent FDA action re: oncology pharmacy including review of the APHINITIY trial and pertuzumab's subsequent approval in the adjuvant setting. Also, the nilotinib label change allowing for discontinuation in CML patients is discussed.